Godrej Agrovet reported a 22% rise in second-quarter net profit to ₹103 crore, driven by growth in its animal nutrition and oil palm segments. While revenue grew 17% to ₹2,995 crore, the company faced margin pressure due to higher input costs. Investors may monitor whether the firm can improve profitability amid ongoing inflationary challenges.
Godrej Agrovet announced its financial results for the second quarter ended September 30, 2026, showing a mix of strong revenue growth and rising operational costs. The company reported a consolidated net profit of ₹103 crore, a 22% increase compared to the same period last year. Revenue from operations also rose 17% to reach ₹2,995 crore, as the company saw demand pickup across key divisions.
Segment Performance and Strategic Shifts
The animal nutrition segment served as a key driver for the quarter, recording a 14% revenue increase and a 32% rise in segment profit. This growth reflects improvements in product mix and operational efficiency. The oil palm business also posted strong results with a 28% increase in revenue. To strengthen its position in the domestic edible oil market, the company is continuing to invest in new plantation capacities and processing facilities, including its recent projects in Khammam.
Management is also refining the company’s business structure to focus on high-margin areas. This includes a decision to exit the shrimp feed business, allowing the company to reallocate resources toward more scalable opportunities. Meanwhile, the international joint venture in Bangladesh, ACI-GAVL, supported the overall performance with a 32% revenue rise.
Margin Pressure and Operational Costs
Despite the top-line growth, profitability was hindered by higher operational expenses. The company’s EBITDA (earnings before interest, tax, depreciation, and amortization) fell by approximately 3% to ₹224 crore. This led to a contraction in operating margins by about 1.5%, settling at 7.49%. Rising input costs, which are sensitive to global commodity prices, have been a challenge for the company's profitability.
Performance across other divisions was varied. The crop care segment achieved a 42% revenue increase, though profitability was impacted by difficult weather conditions and elevated input costs. Additionally, Astec LifeSciences, a subsidiary, saw a 3% revenue decline. While its contract manufacturing business showed some resilience with 15% growth, weak demand in other areas of the business affected the overall segment result.
For investors, the key monitorable will be the company’s ability to protect its profit margins in an inflationary environment. While the firm is focusing on volume growth and better realizations to counter rising costs, the agribusiness sector remains sensitive to monsoon patterns and global commodity price volatility. Moving forward, updates on the commissioning of new facilities and the impact of the strategic shift away from the shrimp feed business will be important factors to track.